Gram-positive organisms such as methicillin-resistant staphylococci, enterococci, group JK diphtheroids, and Bacillus spp. have in recent years emerged as significant pathogens in neutropenic cancer patients (1) . Some investigators advocate the empiric use of vancomycin to reduce the morbidity associated with gram-positive infections (3) . Although most of these organisms are susceptible to vancomycin, alternative agents with significant gram-positive activities are of considerable interest.
Paldimycin (U-70138F), a novel antibiotic, is a mixture of two closely related substances (U-67963 and U-67964) that are derived from paulomycins A and B, respectively, by the addition of two molecules of N-acetyl-L-cysteine. Paldimycin has potent in vitro activity against a variety of gram-positive organisms (B. R. Hannon Paldimycin was supplied by The Upjohn Co., Kalamazoo, Mich., and vancomycin was provided by Eli Lilly & Co., Indianapolis, Ind., in the form of standard powders for laboratory use. A total of 306 gram-positive organisms representing 12 bacterial species were tested. All organisms were isolated from blood culture specimens obtained from cancer patients admitted to this institution during the past 5 years. All organisms were maintained in stock by ultrafreezing methods. The staphylococcal species were identified by the methods described by Kloos et al. (4, 5) . The streptococci were identified and grouped by the methods described by Facklam and Carey (2) . Staphylococcus aureus isolates were considered penicillin G susceptible on the basis of an MIC of <0.1 ,ug/ml, methicillin susceptible on the basis of an * Corresponding author.
MIC of .4.0 ,ug/ml, and methicillin resistant on the basis of an MIC of -8.0 ,ug/ml.
Organisms were inoculated into broth and incubated at 37°C for 18 h. Appropriate dilutions were then made so that the final inoculumn of organisms tested was 105 CFU/ml. The concentration and purity of all isolates were confirmed by plate counting. Susceptibility testing was performed by the guidelines established by the National Committee for Clinical Laboratory Standards (6) . MIC plates were freshly prepared before each susceptibility test run.
The test medium used was cation-supplemented (Ca2+, 50 mg/liter, and Mg2+, 25 mg/liter) Mueller-Hinton broth (MHB; Difco Laboratories, Detroit, Mich.) for all organisms except groUp JK diphtheroids, which were tested in brain heart infusion with 5% rabbit serum, and the streptococci, which were tested in cation-supplemented MHB with 2% lysed horse blood. The in vitro activity of paldimycin is both medium and pH sensitive because of the relative instability of the drug. At 35°C, paldimycin is more stable in Nutrient broth (NB; Difco) at a pH of 6.8 than in MHB at a pH of 7.2, retaining 85.5% of its activity after 6 h and 21.8% of its activity after 24 h in the former, compared with 34 and <13% in the latter (D. L. Griffith and investigators, clinical brochure, Upjohn). We therefore followed manufacturer suggestions and evaluated the activity of paldimycin by using both MHB and NB. The pH of NB was adjusted to 6.8 by using a phosphate buffer.
Antibiotic concentrations were prepared manually with serial twofold dilutions ranging from 0.03 to 64.0 jig/ml and were dispensed automatically by using an MIC-2000 apparatus (Dynatech Laboratories, Inc., Alexandria, Va. The activity of paldimycin was largely medium and pH dependent. When tested in cation-supplemented MHB at a pH of 7.2, the MIC90s for most species were consistently 4-to 16-fold higher than those obtained in NB at a pH of 6.8. Mouse protection studies have shown that MICs obtained by using NB of pH 6.8 were predictive of in vivo activity (data on file, Upjohn).
Infections caused by gram-positive organisms are occurring with greater frequency in most major cancer centers. This increase may be related to an increase in the use of central venous catheters and other intravascular devices and to the empiric use of broad-spectrum antimicrobial therapy. Our data show that paldimycin is a new antimicrobial agent which has promising in vitro activity against gram-positive organisms and may be of use in the therapy of infections caused by these organisms.
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